When cancer leaves only molecular traces, RaDaR ST brings them into view.
MRD detection, personalized to every patient’s tumor
RaDaR ST analyzes each patient's unique tumor profile to develop a personalized panel—then uses that panel to detect the presence or absence of circulating tumor DNA in the patient's bloodstream.
Why choose RaDaR ST for MRD testing?
RaDaR ST provides clear, actionable answers at every major decision point—from adjuvant treatment through long-term surveillance—helping you manage patients with confidence.
 | RaDaR ST detects trace amounts of circulating tumor DNA. |
 | RaDaR ST detects ctDNA and evidence of molecular recurrence, enabling earlier intervention and personalized treatment decisions. |
 | Proven performance built for confident decision-making, and detection as low as 1 ppm.* |
 | RaDaR ST delivers intuitive, easy-to-interpret reports that translate complex molecular data into clear clinical guidance. |
Built for confident decision-making, RaDaR ST offers proven analytical performance with specificity of nearly 100%, detection as low as 1 ppm1. Its ability to detect extremely low levels of circulating tumor DNA enables early, reliable identification of molecular residual disease or recurrence, minimizing false positives and supporting timely care decisions.
RaDaR ST is supported by a growing foundation of clinical and real-world data demonstrating its powerful performance, reliability, and impact across solid tumors. Peer-reviewed studies and multi-center validations show that RaDaR ST consistently correlates MRD status with recurrence risk, treatment response, and patient outcomes—giving you evidence-backed confidence in every result.
Intuitive ordering that fits seamlessly into your clinic’s daily workflow.
From simplified requisitions, online ordering, and flexible sample collection options to personalized assistance for onboarding, troubleshooting, and result interpretation. Minimize administrative burden and ensure your practice always has the support it needs.
Delivering clear and actionable answers with RaDaR ST.
RaDaR ST is Medicare-approved for select solid tumor indications. This coverage helps ensure more patients can benefit from MRD-guided insights while giving your practice greater certainty and smoother billing workflows.
References
Sensitivity demonstrated across four independent analytical and clinical validation studies, with detection of LOD95 at 11 parts per million (ppm) and under certain study-specific conditions, down to 1 ppm. Data on file. (Cabel L, et al. https://pubmed.ncbi.nlm.nih.gov/41611726/, Elliott MJ et al. https://pubmed.ncbi.nlm.nih.gov/39984446/, Stanciu A et al. https://pubmed.ncbi.nlm.nih.gov/41350280/, Schuurbiers MMF et al. https://pubmed.ncbi.nlm.nih.gov/40233104/)